Radium-223 dichloride
Phase 3Small molecule
BayerRadium-223 dichloride is one of 3 small molecule programs targeting Metastatic Castrate Resistant Prostate Cancer (mCRPC). It is currently in Phase 3.
1
Indications
15
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Metastatic Castrate Resistant Prostate Cancer (mcrpc)
#DrugCompanyPhaseTrials
1Xtandi
AstellasPhase 3
PF-06821497
PfizerPhase 3
Radium-223 dichloride
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer9 trials
Show 6 more trials
Prostate Carcinoma1 trial
Non-Small Cell Lung Cancer1 trial
Metastatic Castrate Resistant Prostate Cancer (mCRPC)1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Radium-223 dichloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]